Log in
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

Novo Nordisk A/S Price Target & Analyst Ratings (NYSE:NVO)

+0.18 (+0.29 %)
(As of 01/23/2020 01:29 AM ET)
Today's Range
Now: $61.32
50-Day Range
MA: $58.24
52-Week Range
Now: $61.32
Volume1.22 million shs
Average Volume1.38 million shs
Market Capitalization$145.21 billion
P/E Ratio25.03
Dividend Yield1.05%

Analyst Ratings

Novo Nordisk A/S (NYSE:NVO) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Novo Nordisk A/S in the last 12 months. Their average twelve-month price target is $181.58, suggesting that the stock has a possible upside of 196.11%. The high price target for NVO is $400.00 and the low price target for NVO is $48.61. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score:
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $181.58$181.58$181.58$126.97
Price Target Upside: 196.11% upside221.57% upside266.97% upside142.22% upside

Novo Nordisk A/S (NYSE:NVO) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.


If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Novo Nordisk A/S (NYSE:NVO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
11/27/2019BarclaysUpgradeEqual Weight ➝ OverweightMedium
11/22/2019Pareto SecuritiesDowngradeBuy ➝ HoldLow
11/18/2019UBS GroupDowngradeBuy ➝ NeutralLow
9/17/2019CitigroupUpgradeNeutral ➝ BuyLow
9/13/2019Bank of AmericaBoost Price TargetNeutral$355.00 ➝ $400.00Low
8/30/2019Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
6/20/2019Deutsche BankDowngradeBuy ➝ Hold$52.42Medium
4/29/2019Credit Suisse GroupUpgradeNeutral ➝ OutperformLow
2/4/2019HandelsbankenDowngradeBuy ➝ Accumulate$48.61Low
2/1/2019Morgan StanleyInitiated CoverageEqual WeightLow
1/29/2019BNP ParibasInitiated CoverageOutperformLow
11/29/2018Kepler Capital MarketsReiterated RatingHoldLow
11/26/2018HSBCReiterated RatingSellLow
11/19/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
11/2/2018CfraReiterated RatingHoldLow
7/2/2018Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformLow
(Data available from 1/23/2018 forward)
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel